Paul K. Winner

Paul K. Winner

From Glaxosmithkline, Research Triangle Park, Nc, Usa (S.a. Mcdonald, M.c. Runken, N.e. Richard, And F.j. Derosier); Children's Hospital Medical Center, College Of Medicine, ...

Direct Impact

Concepts for which Paul K Winner has direct influence:

chronic migraine
rizatriptan 5
pediatric headache
2 hours
zolmitriptan nasal spray
cervical dystonia
oral sumatriptan

External impact

Concepts related to the work of other authors for which Paul K Winner has influence:

insufficient responders
nasal sumatriptan
muscle pain
botulinum toxin
chronic migraine
gastric stasis
migrainous headache

Prominent publications by Paul K. Winner

KOL-Index: 40 The management of pediatric migraine requires a balance of biobehavioral measures coupled with agents for acute treatment and, if needed, daily preventive medicines. A recent American Academy of Neurology practice parameter has critically reviewed the limited data regarding the efficacy and safety of medicines for the acute and preventive therapy of pediatric migraine. The first step is to ...
Known for
Safety Medicines | Migraine Step | Preventive Drug | Agents Acute
KOL-Index: 23 OBJECTIVE: As a post-approval commitment, this dose-ranging study was undertaken to evaluate efficacy and safety of onabotulinumtoxinA in adolescents. BACKGROUND: In adolescents, migraine is often undiagnosed or misdiagnosed and can present unique management challenges. OnabotulinumtoxinA was approved for prevention of chronic migraine (CM) in adults in 2010. METHODS: This multicenter, ...
Known for
Trial Assessed | Reduced Frequency | Safety Onabotulinumtoxina | Adolescents Chronic
KOL-Index: 22 BACKGROUND: Treatment of adolescent migraine remains a significant unmet medical need. We compared the efficacy and safety of 3 doses of sumatriptan and naproxen sodium (suma/nap) combination tablets to placebo in the acute treatment of adolescent migraine. METHODS: This randomized, parallel group study in 12 to 17 year olds required 2 to 8 migraines per month (typically lasting >3 hours ...
Known for
12-Week Run-In Phase | 2 Hours | Single-Blind | Hour Pain
KOL-Index: 19 This study examined the effect of age on placebo response rates in rizatriptan trials in adults. Data from eight rizatriptan adult trials involving patients treating moderate/severe migraine attacks with rizatriptan 5 mg (N = 1819), rizatriptan 10 mg (N = 2046) or placebo (N = 1322) were pooled for post hoc analysis. Logistic regression was used to model 2-h pain relief (reduction to mild or ...
Known for
Trials Older | 2-H Pain Relief | Freedom Response | 10-Year Age
KOL-Index: 17 OBJECTIVE: To examine the cardiovascular, cerebrovascular, and peripheral vascular safety of erenumab across migraine prevention studies. METHODS: Vascular adverse events (AEs) and blood pressure data were integrated across 4 double-blind, placebo-controlled studies of erenumab and their open-label extensions in patients with chronic or episodic migraine. Subgroup analyses were conducted by ...
Known for
2 Vascular | Aes Open | Placebo-Controlled | Search Terms
KOL-Index: 17 OBJECTIVE: The primary objective of the TEENZ Study (NCT01211145) was to assess the efficacy of zolmitriptan nasal spray in the acute treatment of adolescent migraine patients (ages 12 to 17 years), as measured by the primary outcome variable of pain-free status at 2 hours post-treatment. METHODS: This randomized, double-blind, placebo-controlled, four-arm parallel group study compared ...
Known for
Completed Period | Recording Headache Pain Scores | Spray Acute | Single Migraine
KOL-Index: 17 Importance: Intravenous eptinezumab, an anti-calcitonin gene-related peptide antibody, is approved for migraine prevention in adults. It has established onset of preventive efficacy on day 1 after infusion. Objective: To evaluate the efficacy of and adverse events related to eptinezumab when initiated during a migraine attack. Design, Setting, and Participants: Phase 3, multicenter, ...
Known for
Headache Symptom | Pain Bothersome | Treatment-Emergent | Severe Migraine
KOL-Index: 13 OBJECTIVE: The goal was to evaluate the efficacy and tolerability of zolmitriptan nasal spray in the treatment of adolescent migraine. METHODS: The "Double-Diamond" study used a novel, single-blind, "placebo challenge" in a multicenter, randomized, double-blind, placebo-controlled, 2-way, 2-attack, crossover design. A total of 248 US adolescent patients (12-17 years of age) with an ...
Known for
Higher Headache Response Rate | Aura | Challenge Zolmitriptan | Normal Activities
KOL-Index: 13 Opinion statementVery limited long-term follow-up data exist for the population of children and adolescents with chronic daily headache (CDH). One abstracted report discusses short-term follow-up on 24 adolescents (peak age 13 years) with CDH; in a 6-month follow-up, more than 50% experienced a reduction of 75% or more in headache frequency, and one third showed an improvement of greater ...
Known for
Cdh Experienced | Adolescents Chronic

From GlaxoSmithKline, Research Triangle Park, NC, USA (S.A. McDonald, M.C. Runken, N.E. Richard, and F.J. Derosier); Children's Hospital Medical Center, College of Medicine, University of Cincinnati, Cincinnati, OH, USA (A.D. Hershey); Children's Hos

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172